 |
||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
 |
 |
 |
 |
|
 |
|
||||||
|
|
|
||||||||||||||
|
Current News + Events |
||||||||||||||
News |
|||||||||||||||
|
Of Planning and Happenstance: A Career Primer "What do you want to do when you finish grad school?””What are you doing after your postdoc?” From parents to PI’s these are questions that you hear. So, what is your answer? Do you even have one? Seating is limited, Please Register By Friday October 31, 2008
Center for Biotechnology-Supported Technology Receives FDA Approval to Enter Clinical Trials for Cancer Therapy September, 2008, Stony Brook, NY: Cornerstone Pharmaceuticals and the Center for Biotechnology, a New York State Center for Advanced Technology, recently announced receiving approval from the FDA to conduct a safety and early efficacy clinical trial of CPI-613, the first in class agent from its Altered Energy Metabolism Directed compound platform. The technology, developed by Drs. Paul Bingham and Zuzana Zachar of Stony Brook University, could potentially provide for a safer more effective chemotherapy for some of the most deadly cancers. Drs. Bingham and Zachar have been working with Cornerstone Pharmaceuticals, the exclusive licensee of the technology, to develop pharmaceutically acceptable analogues for cancer treatment of which CPI-613 is the lead product candidate. 09.24.2008 - Cornerstone Press Release Fundamentals of the Bioscience Industry Program Information Sessions Announced How Will You Measure Up? Whether you plan on continuing in academia or entering the industry workforce, understanding the bioscience industry is an edge you must have. The Center for Biotechnology’s Fundamentals of the Bioscience Industry Program can provide that edge. Attend the information session and meet the Fundamentals Program Alumni Network Executive Committee and Alumni and hear of the outstanding value and benefits of this industry-focused and industry-driven program. Discover new ways of thinking of your current research within the broader context of the dynamic bioscience industry. New York City Information Session: Stony Brook University Information Session: Attendance is free. Seating is on a first come, first served basis.
2008 Life Sciences Summit The Life Sciences Summit is designed to address issues of strategic importance to the life sciences industry and to generate new business opportunities. The event will feature three main tracks covering a diversity of issues related to New Business Opportunities, Innovation &Technology Development, and building a vibrant Workforce. More than 300 industry executives are expected to attend the program. New York Biotechnology Association (NYBA) 17th Annual Meeting - May 19-20, 2008 NYBA 17th Annual Meeting New York Stem Cell Foundation 3rd annual public outreach panel on stem cell research - April 30 Stem Cell Research: Realizing the Promise
Grants Available For Biotech Companies to Exhibit at BIO 2008 2008 Long Island Regional SBIR Workshop March 20, 2008 Biotech R&D Funding Conference in NYC Industrial and Technology Assistance Corporation (ITAC), in conjunction with NYCEDC, will host a Biotech R&D Funding Conference at Columbia University's Lerner Hall on March 18. The event will highlight R&D funding opportunities, including SBIR/STTR and QETC, as well as feature expert speakers, panels and one-on-one meetings with NIH Federal program managers. Columbia University Science and Technology Ventures and Fish & Richardson, P.C. are sponsors for this event.
STAR Center breaks ground on Sept 24, 2007, 11:30 am.  September 24, 2007 - L to R: Dr. Yacov Shamash, Dean College of Engineering & Applied Science and VP Economic Development, Stony Brook University; Dr. Richard Fine, Dean, School of Medicine, Stony Brook University; Edward Reinfurt, Acting Executive Director, NYSTAR; Dr. Shirley Strum Kenny, President, Stony Brook University; New York State Senator John Flanagan; Dr. Clinton Rubin, Director, Center for Biotechnology and Professor & Chair, Dept of Biomedical Engineering, Stony Brook University; Diane Fabel, Director of Operations, Center for Biotechnology (CAT); Dr. Lawrence Weber, Director of Business Development, Center for Sensor Systems (CAT).
The groundbreaking ceremony for the STAR Center in Biotechnology and Bioengineering took place on Monday, September 24th at 11:30 am. Opening remarks were presented by Dr. Shirley Strum Kenny and Mr. Edward Reinfurt, Acting Executive Director, New York State Foundation for Science Technology and Innovation (NYSTAR). The STAR Center will house the translational research activities of the Department of Biomedical Engineering and the Center for Biotechnology. 2007 Life Science Summit Highlights New York State's Initiatives in the Bioscience Industry The 2007 Long Island Life Sciences Summit, held on June 14th at the Hilton Long Island in Melville, New York, was a resounding success. The Center for Biotechnology, in partnership with the Long Island Life Sciences Initiative (LILSI), hosted more than 320 business leaders, representing 100 different organizations. Statewide Consortium Proposed to Propel New York State to the Forefront of Computational Biology - Academic Leaders Seek Partnership with Industry at Life Sciences Summit Long Island, NY-May 30, 2007 Robert McGrath, Ph.D., Provost and Vice President for Brookhaven Laboratory Affairs at Stony Brook University, announced today a proposal by a consortium of major universities to take a coordinated approach in the development and application of computational sciences, especially computational biology, to make New York a national leader in this rapidly emerging field. Computational biology has the potential to vastly improve understanding of basic biological processes and accelerate the discovery and development of life saving drugs and diagnostics. The proposed consortium, which currently includes Stony Brook University, Brookhaven National Laboratory, Columbia University, New York University, Rensselaer Polytechnic Institute, University at Albany, University at Buffalo, and Cornell University, will build upon major new supercomputing systems installed at Stony Brook University/Brookhaven National Laboratory and Rensselaer Polytechnic Institute, as well as the world class technical expertise and resources that already exists at the member institutions. “Our announcement today is targeted toward the bioscience industry and our desire to apply our high performance computational biology capabilities to a broad range of areas of potential commercial interest,” said Provost McGrath. “We are actively seeking industry guidance and support for the Consortium, and the Life Sciences Summit represents a great opportunity to reach out to these companies. The ultimate potential to enhance human health and capture the economic benefit of these activities in New York State is enormous.” The IBM Blue Gene/L supercomputer provided by NYS to Stony Brook and installed at Brookhaven National Laboratory, and the rich heterogeneous computational facility – including a Blue Gene/L supercomputer and Opteron and PowerPC clusters – currently being installed at Rensselaer Polytechnic Institute, will have the combined potential to process over 200 trillion computations/second. Together, these systems comprise several of the most powerful supercomputers in the world available for non-classified research. “With this type of capability and the strengths in computational sciences of the consortium partners, New York will emerge at the forefront of computational biology and computational science in general,” said Shirley Strum Kenny, President of Stony Brook University. “The use of computation in drug design will advance our understanding of important biological processes and dramatically accelerate discovery, and ultimately development, of new therapies. This has tremendous implications for both academic and industrial research programs,” said Samuel Aronson, Ph.D., Director of Brookhaven National Laboratory. "IBM is proud to be working with these leading universities to help make New York State a center of excellence for a critical and emerging area of science and commercial research -- computational biology," said Dave Turek, vice president for deep computing at IBM. "The use of computation to analyze and simulate biological structures is advancing our understanding of invisible processes and accelerating the pace of discovery. The integrated approach of the Consortium will enhance these efforts and significantly improve the State's ability to compete in a vital area of research." Future plans for the Consortium include the formation of a Life Science Industry Steering Committee to help guide development. “The biotechnology industry is constantly seeking faster, more efficient means of developing vital therapies, a goal that computational biology promises to accelerate. We look forward to working with the Consortium to advance this important capability, which will further position New York at the forefront of the industry,” said Nathan Tinker, Executive Director of the New York Biotechnology Association.
2007 Career Development Conference The Center for Biotechnology is proud to be a co-organizer of "What Can You Be With a Ph.D.?" a science and technology career conference. Fundamentals of the Bioscience Industry Program Information Sessions Announced New York City Information Session: Wednesday, September 26, 2007-6:00pm
Attendance is free. Seating is on a first come, first serve basis. Please RSVP online. Stony Brook University Information Session: Monday, October 1, 2007-6:00pm 2007-2008 Biomedical Engineering Seminar Series
Research at the Center of Biotechnology Produces 2004 Intel Finalist and 2004 ISEF Award Winner Daniel Choi, a Syosset High School, Long Island, student, has won multiple awards for his research done in the Applied Bioscience Laboratory at the Center. His research project, "DNA Microarray Analysis of Shewanella Oneidensis Grown for Fuel Cell Use", placed him among the top 40 finalists of the 2004 Intel Science Talent Search. The Intel Science Talent Search, America's oldest and most prestigious pre-college science competition - often considered the "junior Nobel Prize" - provides an incentive for students to develop their scientific interests at an early age and a forum for them to share their ideas with other talented young scientists around the country. Daniel spent a week in Washington, D.C. touring the US Capitol and meet with President George W. Bush at the White House. Intel also awarded Dan with a $5,000 scholarship and an Intel CentrinoTM mobile technology-based notebook computer. The Intel International Science and Engineering Fair (ISEF), the world's only international science fair representing all life sciences for high school students, also recognized Daniel's research at the 2004 ISEF competition. He traveled to Portland, Oregon to compete with 1200 students, representing over 40 countries. He won second place in the Microbiology category and was awarded a $1,500 cash prize. The research project was done under the guidance of Dr. Anil Dhundale, Director of Scientific Affairs, and Ms. Melissa Monaghan, Research Support Specialist. This project was in collaboration with Dr. Jizhong Zhou’s group at Oak Ridge National Labs who provided Shewanella DNA microarrays. For more information about the Intel competitions, please
visit http://www.intel.com/education/sections/section3/index.htm Career Paths in Life
Sciences The Center for Biotechnology, in partnership with the Career Center, is hosting a panel discussion aimed at introducing students to the diverse and exciting career opportunities available in the bioscience industry. An invitation has been extended to all undergraduates and graduate students in the life sciences to attend this event. Key industry representatives from various sectors of the bioscience industry will present an insider look at their own personal careers and provide backgrounds on their roles, responsibilities and career growth potential in their area of specialization. This is a rare opportunity for students to engage in a productive dialogue with industry leaders about realistic career goals, aspirations and their future after graduation. Please register online to reserve your seat. Panel Speakers:
New York (February 21, 2002) – CV Therapeutics and Isis Pharmaceuticals were presented with the seventh Annual Helix Award at the Biotechnology Industry Organization’s CEO & Investor Conference 2002 held at the Waldorf Astoria Hotel in New York. Isis Pharmaceuticals received the award for the emerging company category, and CV Therapeutics was honored in the large-cap category.The Helix Award is the highest award of corporate excellence for the international biotechnology industry. The award is presented based on leadership in three distinct areas of scientific innovation, company growth and corporate citizenship. Past winners include OSI Pharmaceuticals, Inc., of Melville, N.Y.; Genentech, Inc., of South San Francisco, Calif.; The Collaborative Group of Stony Brook, N.Y.; Regeneron Pharmaceuticals, Inc., of Tarrytown, N.Y.; Biogen, Inc. of Cambridge, Mass.; and Immunex of Seattle, Wash. These companies have all exemplified the true spirit of corporate leadership in the biotechnology industry.
"Isis has had a tremendous year with the establishment of several pivotal collaborations with industry leaders, major advances in the clinic and accomplishments in our two divisions, GeneTrove and Ibis Therapeutics," said Stanley T. Crooke, M.D., Ph.D., chairman and CEO of Isis. "We are honored that the industry is recognizing the company's achievements and the work of the more than 400 people at Isis". "I am honored to receive this important award on behalf of my colleagues at CV Therapeutics. This recognition from our peers highlights the critical work that our scientists and clinicians accomplish every day," said Louis G. Lange, M.D., Ph.D., Chairman and CEO of CV Therapeutics. "Our company was founded over ten years ago with a single goal: to find better ways to help patients with cardiovascular disease – still the number one cause of death in the United States. 2001 was highlighted by the positive results from our second pivotal Phase III trial, CARISA, which was presented as a Late Breaking Clinical Trial at the American Heart Association." The Helix Award is presented by the Long Island Life Sciences Initiative (LILSI) and is jointly sponsored by BIO, Stony Brook University and The Center for Biotechnology. The Helix Award is open to public and private U.S. or foreign-based biotechnology companies. An independent panel of judges reviewed the 2002 submissions, and KPMG LLP, an international professional services firm tabulated the results. LILSI is a not-for-profit trade association created to address issues of strategic importance to the biotechnology, pharmaceutical, medical device and life science technology-based industries. LILSI advocates on behalf of public policy that will improve the Long Island region's business climate for life science companies and enhance the research and business infrastructure that is vital to their success. More information on LILSI can be found at www.lilsi.org. The Helix Award is the only award for outstanding corporate achievement
in the global biotechnology industry. It was 2nd Annual Life Sciences Industry Career Development Conference
Center for Biotechnology Helps Form Long Island Life Sciences Initiative The Center for Advanced Technology (CAT) in Medical Biotechnology at Stony Brook University played a key role during December 2001 in the formal establishment of the Long Island Life Sciences Initiative (LILSI), a not-for-profit organization that will focus the collective energies of the pharmaceutical, biotechnology, medical device, and life systems technology sectors on issues of strategic importance to the growth, prosperity, and ultimate success of the life sciences industry on Long Island. With approximately 300 life sciences companies in the region, it is estimated that Long Island represents a full one-third of these industries in New York State. Joseph Scaduto, Business Development Associate at the CAT who will also lead LILSI as part-time Executive Director states, "LILSI will help to organize and assemble the life sciences industry on Long Island, and the potential for economic development in the region is enormous." An important mechanism by which the CAT creates economic impact is through the establishment of infrastructure necessary to foster new areas of scientific investigation, enhance the region's competitive position in pursuit of federal funding, and generate intellectual property that holds potential for economic impact in New York State. The CAT has already been successful in fostering growth of the life sciences industry by serving as a founder of both the Long Island High Technology Incubator (LIHTI) and the New York Biotechnology Association (NYBA). Now as a founder of LILSI, the CAT hopes to contribute to an agenda focused on industry needs that will help cultivate a nurturing environment for business, as well as issues that will facilitate technology development and commercialization of academic research. Diane Fabel, Deputy Director at the CAT, emphasizes that "LILSI will work to attract local, state and federal resources to Long Island in order to help sustain the life sciences industry, creating a cluster of successful, high-growth companies." LILSI will also support and promote workforce development programs that help industry and academic institutions build relationships that will address the industry's current and anticipated workforce needs. "LILSI will serve as a vehicle for economic development
for the Long Island region," Mr. Scaduto asserts, "Long Island
has the technology, business resources, and infrastructure to maximize
its potential as an epicenter for the life sciences regionally, nationally
and globally." Annual Careers in the Bioscience Industry Seminar Series at Stony Brook University This is a must attend seminar series for all graduates in the life sciences, computing and engineering fields. This series aims to increase awareness of career opportunities in the bioscience industry and to promote an interactive environment for communication between industry and the graduate student population. View 2001-2002 Seminar Series Schedule Wednesday, February 27, 2002. 12:30
-1:30 pm To attend this free seminar, please register online. Join Mr.
Joseph Scaduto, Executive Director, Long Island Life Sciences Initiative
(LILSI) and Business Development Associate, Center for Biotechnology as
he discusses the transition from graduate school to a career in the bioscience
industry. He will provide a personal insight into his professional career
development as he outlines critical steps involved in gaining industry
experience through internships, creative networking techniques, diverse
and exciting career opportunities in industry and what a career in business
development entails. This is a must attend seminar for all life sciences
graduates who are serious about pursuing a career in the industry. Don't
miss this opportunity to meet and discuss the realities of working in
industry and the strategies for breaking into the bioscience industry.
Light refreshments will be served. Tuesday, March 12, 2002. 10 am - 12:30 pm To attend this outing, please register online. The Center for Biotechnology is pleased to organize a visit to Pall Corporation. Pall is the global leader in the highly sophisticated filtration, separation and purification industry. From drug discovery, through pre-clinical and clinical trials, to full-scale production, Pall Corporation offers innovative and effective solutions in filtration, separation and purification challenges. All graduate students in the life sciences are invited to take this opportunity to visit Pall's Port Washington facility. Space is limited. Program Driving instructions to Port Washington. This visit is limited to 20 students.Transportation will be provided.
All students requiring a ride to and from Port Washington will meet at
8:30 am (sharp), in front of the Administration Building. Wednesday, Mar 20, 2002. 5 - 7 pm This seminar series is organized by The Center for Biotechnology and the Department of Biomedical Engineering. It is presented in partnership with the Career Center. * Please check back for updated information on speakers. * Note the specific times and different locations for each seminar Directions
to the Alliance Room. Annual Bioscience
Careers Conference: Visions for the Future
The Annual Bioscience Careers Conference on January 17, 2002 was a huge success. More than 200 Masters students, PhDs and Post Doctoral Fellows from the life sciences attended the all day conference at the CUNY Graduate Center in New York City. Participants at the conference represented more than 25 research and academic institutions throughout New York State including NYU, Cornell, Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia, Mount Sinai School of Medicine, Albert Einstein College of Medicine, Cold Spring Harbor Laboratory, Rochester Institute of Technology, CUNY and Stony Brook University.
Distinguished speakers from the bioscience industry presented insightful and engaging presentations on diverse career opportunities in Corporate R&D, Business Development, Investment Banking, Venture Capital, Finance, Law, Marketing, Communications and Investor Relations. The closing plenary, "Visions for the Future" engaged the audience in a thought provoking exploration of the state of New York's bioscience industry and its implication for education and economic development. Participants at the conference had an opportunity to meet with bioscience companies to discuss potential career opportunities. Companies that exhibited included -
The Center for Biotechnology would like to thank Morgan & Finnegan LLP for their sponsorship of the Closing Plenary, "Visions for the Future".
For details on the Annual Bioscience Careers Conference, please click here. back to top |
|
  |
About Dr. Robert Tillman
CV
Therapeutics and Isis Pharmaceuticals win highest award of honor in the
biotechnology industry
